{"title":"CRNDE, a Potential Therapeutic Target in Human Diseases.","authors":"Shiyun Zeng, Yao Xie, Yulan Shi, Fenghua Qu, Xinchen Wang, Yuting Liu, Qingqing Li, Houdong Li, Chengfu Yuan","doi":"10.2174/0113816128339697250306072647","DOIUrl":null,"url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs) are RNA molecules exceeding 200 nucleotides in length with minimal or no protein-coding potential. However, a large number of lncRNAs have been discovered as research has progressed, and the traditional view of these noncoding RNAs does not appear to be entirely correct. Recent research has also unveiled their significant roles in various biological processes, spotlighting lncRNAs' importance. The oncogenic lncRNA, Colorectal tumor Differentially Expressed (CRNDE), is prominently studied in cancer contexts. One study found that the modulation of CRNDE expression led to an improvement in the median survival of cancer patients, extending it from 19.2 months to 32.5 months. Nonetheless, CRNDE also exhibits deregulated expression in non-malignant diseases, influencing their pathologies and serving as a potential biomarker and therapeutic target. For example, in the context of COVID-19, with CRNDE serving as a diagnostic indicator, its diagnostic accuracy attains a value as high as 0.889. This review examines CRNDE's expression in specific human diseases, including non-cancerous and cancerous conditions, its impact on disease progression, the underlying mechanisms, and recent therapeutic approaches.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128339697250306072647","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Long non-coding RNAs (lncRNAs) are RNA molecules exceeding 200 nucleotides in length with minimal or no protein-coding potential. However, a large number of lncRNAs have been discovered as research has progressed, and the traditional view of these noncoding RNAs does not appear to be entirely correct. Recent research has also unveiled their significant roles in various biological processes, spotlighting lncRNAs' importance. The oncogenic lncRNA, Colorectal tumor Differentially Expressed (CRNDE), is prominently studied in cancer contexts. One study found that the modulation of CRNDE expression led to an improvement in the median survival of cancer patients, extending it from 19.2 months to 32.5 months. Nonetheless, CRNDE also exhibits deregulated expression in non-malignant diseases, influencing their pathologies and serving as a potential biomarker and therapeutic target. For example, in the context of COVID-19, with CRNDE serving as a diagnostic indicator, its diagnostic accuracy attains a value as high as 0.889. This review examines CRNDE's expression in specific human diseases, including non-cancerous and cancerous conditions, its impact on disease progression, the underlying mechanisms, and recent therapeutic approaches.
期刊介绍:
Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.